ELANElanco Animal Health Inc
Pharmaceutical Preparations
- Revenue
- $4.7B
- 6.2% YoY
- Operating margin
- —
- EBITDA
- —
- Market cap
- $11.5B
- Employees
- 1,000
- $5M revenue each
- Net debt / EBITDA
- —
- $3.3B net debt
- AI in 10-K
- 2.1
- mentions per 10K words
Takeover score 1 of 13
Fixable underperformance 1 of 7
- TSR below peersYes5 of 5 years3+ of last 5 years
- High CEO pay despite TSRNo$14M medianMedian CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCNo1% of revenueOver 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo36% of assetsOver 40% of assets
- Shareholder dissentNo82% lowest supportAny vote under 80% support
Buyer economics 0 of 4
- Low revenue per employeeNo$5M · 98th pctBottom quartile of its SIC industry
- Quiet on AINo2.1 per 10K words · 56th pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedNo$11.5B market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo$3M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $4.8B | $4.4B | $4.4B | $4.4B | $4.7B | 6.2% |
| Net income | −$483M | −$78M | −$1.2B | $338M | −$232M | 169% |
| Operating cash flow | $483M | $452M | $271M | $541M | $560M | 3.5% |
| Capex | $159M | $171M | $140M | $147M | $276M | 88% |
| Stock-based comp | $66M | $59M | $46M | $55M | $68M | 24% |
Deal filings
None.
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| Dec 22, 2022 | Sachem Head Capital Management LP | SC 13D/A | 2.0% | Passive |
| Sep 9, 2022 | Sachem Head Capital Management LP | SC 13D/A | 6.0% | Passive |
| Dec 15, 2020 | Sachem Head Capital Management LP | SC 13D/A | 5.9% | Active |
| Nov 12, 2020 | Sachem Head Capital Management LP | SC 13D/A | 5.9% | Active |
| Oct 7, 2020 | Sachem Head Capital Management LP | SC 13D | 5.9% | Active |
Insider trading
- Open-market buys, 12 mo
- $3M · 11
- Open-market sells, 12 mo
- $100K · 1
- Net
- $3M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $15M | $38M | 74 | 188 |
| FY2024 | $15M | $9M | 39 | 148 |
| FY2023 | $14M | $17M | 49 | 137 |
| FY2022 | $13M | −$2M | 40 | 136 |
| FY2021 | $12M | $17M | 93 | 126 |